Temybric Ellipta यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

temybric ellipta

glaxosmithkline trading services limited - fluticasone furoate, bromur tal-umeclidinium, trifenatate tal-vilanterol - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - temybric ellipta huwa indikat bħala kura ta 'manteniment f'pazjenti adulti b'indeboliment moderat jew sever tal-marda pulmonari ostruttiva kronika (copd) li ma jkunux qed jiġu kkurati b'taħlita ta' kortikosterojdi meħuda man-nifs u li jaħdem fit-tul β2-agonist jew kombinazzjoni ta taġixxi fit-tul β2-agonist u li jaħdem fit-tul muskariniċi antagonist (għall-effetti fuq il-kontroll tas-sintomi u l-prevenzjoni tal-aggravar tal-attakki ara sezzjoni 5.

Isturisa यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

isturisa

recordati rare diseases - osilodrostat phosphate - is-sindromu ta 'cushing - kortikosterojdi għal użu sistemiku - isturisa huwa indikat għall-kura ta ' l-sindromu ta'cushing fl-adulti.

Blenrep यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

blenrep

glaxosmithkline (ireland) limited - belantamab mafodotin - majloma multipla - aġenti antineoplastiċi - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Zynrelef यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

zynrelef

heron therapeutics, b.v. - bupivacaine, meloxicam - uġigħ, wara l-operazzjoni - anestetiċi - zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.

Fintepla यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

fintepla

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - anti-epilettiċi, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

Exparel liposomal यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

exparel liposomal

pacira ireland limited - bupivacaine - acute pain - amides, anesthetics, local - exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.

Orladeyo यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

orladeyo

biocryst ireland limited - berotralstat dihydrochloride - angioedemas, ereditarji - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Copiktra यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

copiktra

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - aġenti antineoplastiċi - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.

Tecovirimat SIGA यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

tecovirimat siga

siga technologies netherlands b.v. - tecovirimat - poxviridae infections; cowpox; monkeypox; vaccinia; smallpox - antivirali għal użu sistemiku - tecovirimat siga is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- smallpox- monkeypox- cowpoxtecovirimat siga is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4. 4 u 5. tecovirimat siga should be used in accordance with official recommendations.

Xevudy यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

xevudy

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - sera immuni u immunoglobulini, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.